What is KRAIG BIOCRAFT LABS INC's earnings per share (EPS)?

KRAIG BIOCRAFT LABS INC (KBLB) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

KRAIG BIOCRAFT LABS INC (KBLB) Financials

KBLB

FY2025 annual

Net Income -$3.6M -6.6% YoY

EPS (Diluted) $0.00 YoY not available

Free Cash Flow -$1.8M +2.7% YoY

Operating Cash Flow -$1.8M +2.7% YoY

Market Cap $103.7M as of Oct 9, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KBLB SEC filings page.

This page shows KRAIG BIOCRAFT LABS INC (KBLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KBLB FY2025 2026-10-03

The company operates with recurring cash needs, a deeply negative equity base, and financing inflows that offset ongoing operating outflows.

In FY2025, the net loss was $3.62M while operating cash flow was -$1.79M; accounting losses therefore did not translate one-for-one into cash use. Operating loss worsened from $3.07M in FY2024 to $3.37M, yet operating cash outflow eased slightly, pointing to a meaningful gap between reported earnings and near-term cash movement.

Operating cash flow was -$1.79M and free cash flow was -$1.79M in FY2025. With capital expenditures at only $5K, the cash requirement is primarily operating activity rather than fixed-asset investment.

Liabilities were $10.6M against assets of $2.6M in FY2025. That gap leaves equity negative at -$8.0M and the current ratio at 0.2, while financing cash flow of $2.5M helped offset the year's operating outflow.

Financial Health Signals

Financial health score not available

KRAIG BIOCRAFT LABS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

KRAIG BIOCRAFT LABS INC passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

KRAIG BIOCRAFT LABS INC reported a net loss of $3.6M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

KRAIG BIOCRAFT LABS INC reported an operating loss of $3.4M against $571K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$696K

YoY-10.2%

QoQ+15.0%

KRAIG BIOCRAFT LABS INC's EBITDA was -$696K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.2% from the same quarter a year earlier. Against the prior quarter it is up 15.0%.

Net Income

-$910K

YoY-25.3%

QoQ+3.5%

KRAIG BIOCRAFT LABS INC reported -$910K in net income in Q2 2026. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is up 3.5%.

EPS (Diluted)

$0.00

KRAIG BIOCRAFT LABS INC earned $0.00 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$627K

QoQ-15.3%

KRAIG BIOCRAFT LABS INC recorded an outflow of $627K in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is down 15.3%.

Cash & Debt

$3.4M

YoY+331.8%

QoQ+17.3%

KRAIG BIOCRAFT LABS INC held $3.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

Diluted avg 1.11B

KRAIG BIOCRAFT LABS INC had a weighted average of 1.11B diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$64K

YoY+0.8%

QoQ-3.5%

KRAIG BIOCRAFT LABS INC invested $64K in research and development in Q2 2026. This represents an increase of 0.8% from the same quarter a year earlier. Against the prior quarter it is down 3.5%.

Capital Expenditures

$29K

QoQ+102.7%

KRAIG BIOCRAFT LABS INC invested $29K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 102.7%.

Share Buybacks

Not reported for Q2 2026.

KBLB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KBLB quarterly income statement

Metric	TTM	FY25POS AM	FY24POS AM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$402K+312.7%	$97K+205.5%	$32K	$0	$0	$0	$0	$0
R&D Expenses	N/A	$166K+0.8%	$164K-30.9%	$238K+34.8%	$176K-10.8%	$198K+123.5%	$88K-60.3%	$223K+50.6%	$148K-42.8%	$259K-34.8%	$397K-8.1%	$432K-1.7%	$440K-10.2%	$489K	N/A	$251K
SG&A Expenses	N/A	$2.0M+12.1%	$1.7M+20.2%	$1.5M+76.2%	$825K-44.8%	$1.5M-57.5%	$3.5M+148.8%	$1.4M+174.1%	$516K	N/A	$1.7M+88.6%	$921K+2.8%	$896K-31.6%	$1.3M+245.3%	$379K-51.8%	$787K
Operating Income	N/A	-$3.4M-9.8%	-$3.1M-17.6%	-$2.6M-23.3%	-$2.1M+23.1%	-$2.8M+39.1%	-$4.5M-72.9%	-$2.6M-173.1%	-$960K	N/A	N/A	N/A	-$1.8M	N/A	N/A	N/A
EBITDA	N/A	-$3.3M-9.9%	-$3.0M-17.8%	-$2.6M-23.6%	-$2.1M+23.4%	-$2.7M+39.3%	-$4.5M-73.9%	-$2.6M-177.6%	-$933K	N/A	N/A	N/A	-$1.8M	N/A	N/A	N/A
Interest Expense	N/A	$571K+7.8%	$530K+9.3%	$485K+214.8%	$154K-35.3%	$238K+4245.9%	$5K-98.1%	$294K+28.6%	$229K+29.3%	$177K+27.0%	$139K+37.3%	$102K+46.6%	$69K+5.6%	$66K+43.5%	$46K	$0
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$3.6M-6.6%	-$3.4M-12.2%	-$3.0M+21.1%	-$3.8M+52.2%	-$8.0M-61.8%	-$5.0M-70.8%	-$2.9M-148.9%	-$1.2M	N/A	N/A	N/A	-$1.9M	N/A	N/A	N/A
EPS (Basic)	N/A	$0.00	$0.00	$0.00	$0.00+100.0%	-$0.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	$0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1.06B+2.0%	1.04B+0.5%	1.03B+6.0%	974M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24POS AM	Q3'2410-Q
R&D Expenses	$64K+0.8%	$67K+179.4%	N/A	$9K-63.0%	$64K+29.3%	$24K-18.9%	N/A	$25K-36.2%
SG&A Expenses	$374K+8.8%	$496K+60.5%	N/A	$1.2M+484.5%	$344K-68.7%	$309K+87.9%	N/A	$205K-8.6%
Operating Income	-$703K-10.3%	-$826K-42.2%	N/A	-$1.4M-238.3%	-$638K+57.1%	-$580K-29.4%	N/A	-$424K+7.8%
EBITDA	-$696K-10.2%	-$819K-42.5%	N/A	-$1.4M-242.3%	-$632K+57.3%	-$575K-30.1%	N/A	-$417K+7.7%
Interest Expense	$151K+6.6%	$148K+5.8%	N/A	$144K+8.6%	$142K+8.5%	$140K+8.0%	N/A	$133K+9.0%
Net Income	-$910K-25.3%	-$943K-57.1%	N/A	-$1.5M-248.5%	-$726K+54.8%	-$600K-18.1%	N/A	-$433K+21.1%
EPS (Basic)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Diluted Shares (Avg)	1.11B+6.0%	1.09B+4.7%	N/A	1.07B+2.9%	1.05B+0.9%	1.04B+0.3%	N/A	1.04B+0.5%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

KBLB Balance Sheet

KBLB quarterly balance sheet

Metric	FY25POS AM	FY24POS AM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$2.6M+70.4%	$1.5M-53.4%	$3.2M-29.3%	$4.6M+51.3%	$3.0M+136.6%	$1.3M+70.1%	$751K+951.9%	$71K-37.7%	$114K-70.2%	$384K+25.8%	$305K-43.4%	$539K+73.3%	$311K+295.2%	$79K-64.8%	$224K
Current Assets	$1.9M+152.4%	$740K-71.2%	$2.6M-35.4%	$4.0M+68.4%	$2.4M+188.7%	$819K+422.7%	$157K+662.7%	$21K-57.6%	$48K-85.4%	$332K+38.9%	$239K-51.9%	$496K+66.9%	$297K+377.4%	$62K-69.1%	$201K
Cash & Equivalents	$1.8M+165.9%	$673K-73.6%	$2.6M-33.9%	$3.9M+64.0%	$2.4M+188.3%	$817K+553.4%	$125K+812.8%	$14K-24.5%	$18K-93.9%	$299K+25.5%	$238K-51.9%	$495K+67.6%	$295K+449.2%	$54K-72.5%	$195K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$29K+322.2%	$7K0.0%	$7K+4.6%	$7K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$26K-18.8%	$32K	$0	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.6M+9.4%	$9.7M+8.0%	$8.9M+10.5%	$8.1M-2.7%	$8.3M+5.9%	$7.9M+27.9%	$6.1M+35.5%	$4.5M+29.8%	$3.5M+27.2%	$2.7M+24.6%	$2.2M+24.8%	$1.8M+16.7%	$1.5M+24.7%	$1.2M+7.4%	$1.1M
Current Liabilities	$10.4M+8.6%	$9.6M+8.2%	$8.9M+10.1%	$8.1M-1.1%	$8.2M+9.6%	$7.5M+33.4%	$5.6M+23.3%	$4.5M+29.8%	$3.5M+27.2%	$2.7M+24.6%	$2.2M+24.8%	$1.8M+16.7%	$1.5M+25.7%	$1.2M+7.8%	$1.1M
Non-Current Liabilities	$119K+194.3%	$41K-25.5%	$54K+162.7%	$21K-86.7%	$155K-61.2%	$400K-27.9%	$555K	$0	$0	$0	$0	$0	$0-100.0%	$9K-30.3%	$13K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$9K	N/A
Total Equity	-$8.0M+1.8%	-$8.1M-42.8%	-$5.7M-62.0%	-$3.5M+33.5%	-$5.3M+19.4%	-$6.6M-22.0%	-$5.4M-20.8%	-$4.5M-32.1%	-$3.4M-43.0%	-$2.4M-24.5%	-$1.9M-54.8%	-$1.2M-2.0%	-$1.2M-5.9%	-$1.1M-25.1%	-$906K
Retained Earnings	-$56.7M-6.8%	-$53.1M-6.8%	-$49.7M-6.5%	-$46.7M-9.0%	-$42.8M-23.1%	-$34.8M-16.7%	-$29.8M-10.8%	-$26.9M-4.5%	-$25.7M-10.0%	-$23.4M-15.1%	-$20.3M-11.7%	-$18.2M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24POS AM	Q3'2410-Q
Total Assets	$4.3M+168.4%	$3.7M+182.8%	$2.6M+70.4%	$2.4M+16.3%	$1.6M-28.3%	$1.3M-52.5%	$1.5M-53.4%	$2.0M-44.1%
Current Assets	$3.6M+326.1%	$3.0M+565.0%	$1.9M+152.4%	$1.6M+32.5%	$839K-45.3%	$453K-78.0%	$740K-71.2%	$1.2M-58.7%
Cash & Equivalents	$3.4M+331.8%	$2.9M+628.2%	$1.8M+165.9%	$1.6M+31.6%	$785K-48.4%	$397K-80.6%	$673K-73.6%	$1.2M-58.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$134K+1848.6%	$74K+979.4%	$29K+322.2%	$29K+322.2%	$7K0.0%	$7K0.0%	$7K0.0%	$7K+4.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.0M+9.5%	$10.8M+9.3%	$10.6M+9.4%	$10.3M+9.9%	$10.1M+9.5%	$9.9M+9.4%	$9.7M+8.0%	$9.4M+8.8%
Current Liabilities	$10.9M+8.7%	$10.7M+8.7%	$10.4M+8.6%	$10.2M+9.0%	$10.0M+9.7%	$9.8M+9.7%	$9.6M+8.2%	$9.3M+9.0%
Non-Current Liabilities	$121K+251.2%	$106K+182.1%	$119K+194.3%	$128K+200.8%	$34K-24.1%	$38K-34.9%	$41K-25.5%	$43K-22.3%
Total Equity	-$6.8M+20.3%	-$7.1M+17.4%	-$8.0M+1.8%	-$8.0M-8.1%	-$8.5M-21.5%	-$8.5M-36.9%	-$8.1M-42.8%	-$7.4M-47.2%
Retained Earnings	-$58.6M-7.6%	-$57.7M-7.4%	-$56.7M-6.8%	-$55.9M-7.1%	-$54.4M-5.0%	-$53.7M-7.0%	-$53.1M-6.8%	-$52.2M-8.0%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.

KBLB Cash Flow Statement

KBLB quarterly cash flow statement

Metric	TTM	FY25POS AM	FY24POS AM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$2.0M	-$1.8M+2.7%	-$1.8M-47.8%	-$1.2M+34.1%	-$1.9M-4.8%	-$1.8M-43.5%	-$1.3M-15.3%	-$1.1M-362.9%	-$235K	N/A	-$1.0M-4.6%	-$968K-7.0%	-$905K-13.0%	-$800K	N/A	-$556K
Depreciation & Amortization	N/A	$25K-4.0%	$26K-5.3%	$28K-1.7%	$28K+7.5%	$26K-6.9%	$28K-8.8%	$31K+15.6%	$27K+31.3%	$20K+19.5%	$17K+10.1%	$15K+115.4%	$7K+21.6%	$6K+5.5%	$6K+4.0%	$5K
Stock-Based Compensation	N/A	$87K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$550K+76.3%	$312K
Capital Expenditures	$44K	$5K+27.2%	$4K-33.7%	$6K+27.4%	$5K-94.8%	$97K	N/A	$101K+780.4%	$11K-63.3%	$31K+1152.7%	$2K-93.7%	$39K-6.0%	$42K+1103.7%	$3K	$0-100.0%	$1K
Free Cash Flow	-$2.1M	-$1.8M+2.7%	-$1.8M-47.4%	-$1.3M+33.9%	-$1.9M+0.3%	-$1.9M	N/A	-$1.2M-382.3%	-$246K	N/A	-$1.0M-0.7%	-$1.0M-6.4%	-$946K-17.8%	-$804K	N/A	-$557K
Investing Cash Flow	$252K	$438K+10431.2%	-$4K+33.7%	-$6K-27.4%	-$5K+99.1%	-$547K	N/A	-$101K-780.4%	-$11K+63.3%	-$31K-1152.7%	-$2K+93.7%	-$39K+6.0%	-$42K-1103.7%	-$3K-1708.9%	-$192+97.3%	-$7K
Financing Cash Flow	$4.4M	$2.5M+7102.3%	-$35K+41.3%	-$60K-101.8%	$3.4M-12.5%	$3.9M+99.6%	$1.9M+49.7%	$1.3M+437.2%	$242K-49.6%	$480K-55.3%	$1.1M+43.3%	$750K-34.6%	$1.1M+9.6%	$1.0M	N/A	$666K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24POS AM	Q3'2410-Q
Operating Cash Flow	-$599K-35.1%	-$530K-21.9%	-$449K+12.3%	-$462K-41.6%	-$443K+13.2%	-$434K+11.2%	-$513K-56.4%	-$326K-31.2%
Depreciation & Amortization	$7K+21.7%	$6K+9.5%	$8K+25.6%	$6K-9.9%	$6K-13.3%	$6K-15.5%	$6K-20.1%	$7K-8.7%
Stock-Based Compensation	N/A	$29K	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	$29K	$14K	$2K	$0	N/A	N/A	N/A	N/A
Free Cash Flow	-$627K	-$544K	-$451K	-$462K	N/A	N/A	N/A	N/A
Investing Cash Flow	-$29K	-$14K	$72K	$223K	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.1M+63.9%	$1.6M+939.3%	$602K	$1.0M+19538.1%	$688K+4687.5%	$158K+1154.9%	$0+100.0%	-$5K+65.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KBLB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KBLB quarterly financial ratios

Metric	FY25POS AM	FY24POS AM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-239.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-291.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-141.2%+84.6pp	-225.8%-132.1pp	-93.7%-9.7pp	-84.0%+182.2pp	-266.3%+123.0pp	-389.2%-1.7pp	-387.5%+1250.1pp	-1637.6%	N/A	N/A	N/A	-347.4%	N/A	N/A	N/A
Current Ratio	0.18+0.1x	0.08-0.2x	0.29-0.2x	0.49+0.2x	0.29+0.2x	0.11+0.1x	0.030.0x	0.000.0x	0.01-0.1x	0.120.0x	0.11-0.2x	0.28+0.1x	0.20+0.1x	0.05-0.1x	0.18
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	5.63+4.8x	0.85+0.8x	0.08+0.1x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-61.4%	N/A	-3183.9%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24POS AM	Q3'2410-Q
Return on Assets	-21.3%+24.3pp	-25.3%+20.3pp	N/A	-64.1%-42.7pp	-45.6%+26.7pp	-45.6%-27.3pp	N/A	-21.4%-6.2pp
Current Ratio	0.33+0.2x	0.28+0.2x	0.18+0.1x	0.160.0x	0.08-0.1x	0.05-0.2x	0.08-0.2x	0.13-0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.18), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
KRAIG BIOCRAFT LABS INC KBLB	FY2025	N/A	-$3.6M	N/A	$103.7M	—
BLUE BIOFUELS INC BIOF	FY2025	N/A	-$2.9M	N/A	$35.3M	—
GREYSTONE LOGISTICS INC GLGI	FY2026	$27.5M	-$8.2M	-29.9%	$5.7M	—

Where KRAIG BIOCRAFT LABS INC Ranks

Frequently Asked Questions

Is KRAIG BIOCRAFT LABS INC profitable?

No, KRAIG BIOCRAFT LABS INC (KBLB) reported a net income of -$3.6M in fiscal year 2025.

What is KRAIG BIOCRAFT LABS INC's EBITDA?

KRAIG BIOCRAFT LABS INC (KBLB) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is KRAIG BIOCRAFT LABS INC's free cash flow?

KRAIG BIOCRAFT LABS INC (KBLB) recorded an outflow of $1.8M in free cash flow during fiscal year 2025. This represents a 2.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is KRAIG BIOCRAFT LABS INC's operating cash flow?

KRAIG BIOCRAFT LABS INC (KBLB) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are KRAIG BIOCRAFT LABS INC's total assets?

KRAIG BIOCRAFT LABS INC (KBLB) had $2.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are KRAIG BIOCRAFT LABS INC's capital expenditures?

KRAIG BIOCRAFT LABS INC (KBLB) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does KRAIG BIOCRAFT LABS INC spend on research and development?

KRAIG BIOCRAFT LABS INC (KBLB) invested $166K in research and development during fiscal year 2025.

How many shares does KRAIG BIOCRAFT LABS INC have outstanding?

KRAIG BIOCRAFT LABS INC (KBLB) had 1.10B shares outstanding as of fiscal year 2025.

What is KRAIG BIOCRAFT LABS INC's current ratio?

KRAIG BIOCRAFT LABS INC (KBLB) had a current ratio of 0.18 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is KRAIG BIOCRAFT LABS INC's return on assets (ROA)?

KRAIG BIOCRAFT LABS INC (KBLB) had a return on assets of -141.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is KRAIG BIOCRAFT LABS INC's P/E ratio?

KRAIG BIOCRAFT LABS INC (KBLB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $103.7M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is KRAIG BIOCRAFT LABS INC's price-to-sales ratio?

KRAIG BIOCRAFT LABS INC (KBLB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $103.7M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does KRAIG BIOCRAFT LABS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, KRAIG BIOCRAFT LABS INC (KBLB) held $1.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.8M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is KRAIG BIOCRAFT LABS INC's debt-to-equity ratio negative or not reported?

KRAIG BIOCRAFT LABS INC (KBLB) has negative shareholder equity of -$8.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is KRAIG BIOCRAFT LABS INC's Piotroski F-Score?

KRAIG BIOCRAFT LABS INC (KBLB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are KRAIG BIOCRAFT LABS INC's earnings high quality?

KRAIG BIOCRAFT LABS INC (KBLB) reported a net loss of $3.6M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can KRAIG BIOCRAFT LABS INC cover its interest payments?

KRAIG BIOCRAFT LABS INC (KBLB) reported an operating loss of $3.4M against $571K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.